Monday, October 6, 2025

Latest

Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract

Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this morning announced a partnership with KGK Science, whereby it will begin studying a psilocybin extract produced in its lab.

The clinical trial is to study the safety and psychoactive properties of a Psilocybe mushroom product that has been extracted and formulated by the study. Classified as a phase 1 trial, the trial is to consist of 14 volunteers that will be used to assess the safety and efficacy of such a product, which will then be used in further trials, or under compassionate-use guidelines.

The study is expected to create IP for the company while also enabling further studies to be conducted in the future.

Numinus Wellness last traded at $1.08 on the TSX Venture.


Information for this briefing was found via Sedar and Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Numinus Sells Utah Clinics For US$3.53 Million

Numinus Wellness (TSX: NUMI) is disposing of its US-based clinics in a transaction that is...

Friday, November 15, 2024, 08:03:39 AM

Numinus Wellness Receives Health Canada Amendment To Study Psilocybin Extraction

Numinus Wellness (TSXV: NUMI) this morning had a significant update, announcing that it has received...

Thursday, June 11, 2020, 09:10:28 AM

Quebec Makes History As First Province in Canada to Cover Psilocybin-Assisted Psychotherapy

Last week, Quebec became the first governing medical body in Canada to publicly fund medical...

Wednesday, December 21, 2022, 12:48:00 PM

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its...

Tuesday, August 10, 2021, 08:36:06 AM

Australia Becomes First to Reclassify MDMA and Psilocybin As Medicine for Specific Uses

Australia has become the first country in the world to re-classify the psychedelic substances psilocybin...

Monday, February 13, 2023, 03:47:00 PM